Skip to main content

Denmark s Exiqon A/S Takes $3 Million Funding

NEW YORK, February 12 -- Exiqon A/S of Copenhagen, Denmark, today announced a fourth-round funding of $3 million.


The company said the funding follows a restructuring and layoffs. Details were not available. Investors in the round include Danske Bank, LD, Nobel Group, Scandinavian Life Sciences Venture, and Teknoinvest, the company said. Exiqon will seek an additional $1.5 million in capital, the company said in a statement.


The company is commercializing the synthesis and applications of LNA, a novel high-affinity DNA analog with the promise of creating specificity and affinity for conventional DNA-based techniques, the company said.


The firm is hoping that the funding, and the restructuring, will help it bridge the gap between development and commercialization, or "until sufficient license revenues are secured by first quarter 2004," the company said in a statement.


The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.